PureIR
中文
Menu
About PureIR Yonghe MedicalBeauty FarmAngelalignChaoju Eye CareYidu Tech Editorial method

HKEX 02219 · Unpaid pilot profile

Chaoju Eye Care

Chaoju Eye Care Holdings Limited

Chaoju Eye Care is an ophthalmic medical service group in North China providing consumer and basic ophthalmic services. In 2025 it reported revenue of RMB1,360.360 million, net profit of RMB177.408 million and a gross margin of 42.2%; at year-end it operated 31 ophthalmic hospitals and 32 optical centres across seven provinces, municipalities and autonomous regions.

Disclosure through2025-12-31 Page reviewed2026-07-17 Listed onHong Kong Stock Exchange
Official investor-relations website CJ@chaojueye.com Corporate profile · 2025 annual report · PDF page 6

This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement.

A lens that brings the distance back into focus 00

Tap the lens and move from haze into clarity and warmth

  1. 01Basic ophthalmology
  2. 02Consumer ophthalmology
  3. 03Hospitals and optical centres
  4. 04Ongoing medical services

An editorial metaphor for the disclosed dual-pillar business and medical network; it does not represent an individual clinical outcome.

RMB339.4m Net operating cash flow Year ended 31 December 2025 31 hospitals Ophthalmic hospital network As at 31 December 2025 HK$0.2423/share Proposed final dividend Year ended 31 December 2025 Continue through the disclosure

Disclosure highlights

Latest disclosed facts

Cover of Chaoju Eye Care 2025 annual report
Chaoju Eye Care 2025 annual report · HKEX
01

Net operating cash flow

RMB339.4m

The company remained operating-cash-flow positive in a year when revenue decreased by 3.2%.

Year ended 31 December 2025 · RMB million HKEX · PDF page 27
02

Ophthalmic hospital network

31 hospitals

The network also included 32 optical centres across seven provinces, municipalities and autonomous regions.

As at 31 December 2025 · ophthalmic hospitals HKEX · PDF page 11
03

Proposed final dividend

HK$0.2423/share

A Board recommendation disclosed in the annual report, subject to shareholder approval; the FY2024 final dividend of HKD0.1193 per share had been paid.

Year ended 31 December 2025 · HKD per share HKEX · PDF page 31

Disclosure reading

How to read the disclosure

PureIR disclosure synthesis

Two pillars: consumer and basic ophthalmic services

Consumer and basic ophthalmic services represented 50.7% and 49.1% of 2025 revenue. The former includes refractive correction, myopia control and optical products; the latter covers common eye diseases such as cataract, glaucoma and fundus diseases.

HKEX · PDF page 12

PureIR disclosure synthesis

Regional clusters and a standardised network

Originating from a Baotou eye clinic founded in 1988, the Group operated 31 hospitals in regional clusters at the end of 2025, supported by centralised and standardised management.

HKEX · PDF page 6

PureIR disclosure synthesis

Operating resilience amid pricing pressure

The company disclosed revenue pressure from intensified competition, medical-insurance service pricing reform and volume-based procurement of intraocular lenses; net operating cash flow was RMB339.4 million.

HKEX · PDF page 11

Business model

Business revenue

Consumer ophthalmic services revenue

RMB 689.538 million FY2025 PDF page 12

Basic ophthalmic services revenue

RMB 667.639 million FY2025 PDF page 12

Other / equipment and medical-consumables sales

RMB 3.183 million FY2025 PDF page 12

Annual series

Revenue mix by business (RMB)

Revenue mix by business (RMB), unit: RMB million 1,518 1,138 759 379 0 FY2021FY2022FY2023FY2024FY2025 Consumer ophthalmic services revenue FY2021: 517.2 RMB million Basic ophthalmic services revenue FY2021: 479.7 RMB million Other / equipment and medical-consumables sales FY2021: 0.8 RMB million Consumer ophthalmic services revenue FY2022: 542.9 RMB million Basic ophthalmic services revenue FY2022: 447.2 RMB million Other / equipment and medical-consumables sales FY2022: 0.0 RMB million Consumer ophthalmic services revenue FY2023: 709.2 RMB million Basic ophthalmic services revenue FY2023: 654.0 RMB million Other / equipment and medical-consumables sales FY2023: 6.3 RMB million Consumer ophthalmic services revenue FY2024: 706.4 RMB million Basic ophthalmic services revenue FY2024: 697.8 RMB million Other / equipment and medical-consumables sales FY2024: 1.2 RMB million Consumer ophthalmic services revenue FY2025: 689.5 RMB million Basic ophthalmic services revenue FY2025: 667.6 RMB million Other / equipment and medical-consumables sales FY2025: 3.2 RMB million
Period: complete fiscal years; business revenue follows company definitions; unit：RMB million；type: company disclosure. FY2021 formal disclosure, PDF page 11; FY2022 formal disclosure, PDF page 12; FY2023 formal disclosure, PDF page 11; FY2025 formal disclosure, PDF page 12
View exact values and source pages
MetricPeriodValueSource
Consumer ophthalmic services revenueFY2021RMB 517.233 millionPDF page 11
Basic ophthalmic services revenueFY2021RMB 479.712 millionPDF page 11
Other / equipment and medical-consumables salesFY2021RMB 0.842 millionThis line was disclosed as “Others” in the FY2021 annual report.PDF page 11
Consumer ophthalmic services revenueFY2022RMB 542.873 millionPDF page 12
Basic ophthalmic services revenueFY2022RMB 447.171 millionPDF page 12
Other / equipment and medical-consumables salesFY2022RMB 0 millionThe FY2022 annual report displayed a dash for this line; the chart shows zero so the business lines reconcile to revenue.PDF page 12
Consumer ophthalmic services revenueFY2023RMB 709.225 millionPDF page 11
Basic ophthalmic services revenueFY2023RMB 654.011 millionPDF page 11
Other / equipment and medical-consumables salesFY2023RMB 6.269 millionThis line was disclosed as sales of equipment in the FY2023 annual report.PDF page 11
Consumer ophthalmic services revenueFY2024RMB 706.445 millionPDF page 12
Basic ophthalmic services revenueFY2024RMB 697.84 millionPDF page 12
Other / equipment and medical-consumables salesFY2024RMB 1.169 millionFrom FY2024 this line was disclosed as sales of equipment and medical consumables.PDF page 12
Consumer ophthalmic services revenueFY2025RMB 689.538 millionPDF page 12
Basic ophthalmic services revenueFY2025RMB 667.639 millionPDF page 12
Other / equipment and medical-consumables salesFY2025RMB 3.183 millionThis line was disclosed as sales of equipment and medical consumables.PDF page 12

Structured disclosure

Financial performance

Gross profit

RMB 573.901 million FY2025 PDF page 5

Net profit

RMB 177.408 million FY2025 PDF page 5

Annual series

Revenue and gross profit (RMB)

Revenue and gross profit (RMB), unit: RMB million 1,518 1,138 759 379 0 FY2021FY2022FY2023FY2024FY2025 Revenue FY2021: 997.8 RMB million Revenue FY2022: 990.0 RMB million Revenue FY2023: 1,369.5 RMB million Revenue FY2024: 1,405.5 RMB million Revenue FY2025: 1,360.4 RMB million Gross profit FY2021: 448.7 RMB million Gross profit FY2022: 434.7 RMB million Gross profit FY2023: 621.1 RMB million Gross profit FY2024: 611.3 RMB million Gross profit FY2025: 573.9 RMB million
Period: complete fiscal years; fiscal year-end follows company disclosure; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 5

Annual series

Net profit (RMB)

Net profit (RMB), unit: RMB million 238 179 119 60 0 FY2021FY2022FY2023FY2024FY2025 Net profit FY2021: 157.6 RMB million Net profit FY2022: 183.2 RMB million Net profit FY2023: 220.7 RMB million Net profit FY2024: 186.2 RMB million Net profit FY2025: 177.4 RMB million
Period: complete fiscal years; fiscal year-end follows company disclosure; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 5
View exact values and source pages
MetricPeriodValueSource
RevenueFY2021RMB 997.787 millionPDF page 5
Gross profitFY2021RMB 448.674 millionPDF page 5
Net profitFY2021RMB 157.641 millionPDF page 5
RevenueFY2022RMB 990.044 millionPDF page 5
Gross profitFY2022RMB 434.697 millionPDF page 5
Net profitFY2022RMB 183.196 millionPDF page 5
RevenueFY2023RMB 1,369.505 millionPDF page 5
Gross profitFY2023RMB 621.134 millionPDF page 5
Net profitFY2023RMB 220.735 millionPDF page 5
RevenueFY2024RMB 1,405.454 millionPDF page 5
Gross profitFY2024RMB 611.302 millionPDF page 5
Net profitFY2024RMB 186.21 millionPDF page 5
RevenueFY2025RMB 1,360.36 millionPDF page 5
Gross profitFY2025RMB 573.901 millionPDF page 5
Net profitFY2025RMB 177.408 millionPDF page 5
Gross marginFY202542.2%PDF page 5

Structured disclosure

Operating metrics

Outpatient visits

1,061,851 visits FY2025 PDF page 11

Ophthalmic hospitals

31 hospitals 2025-12-31 PDF page 11

Annual series

Patient visits

Patient visits, unit: visits 1,228,761 921,571 614,381 307,190 0 FY2021FY2022FY2023FY2024FY2025 Outpatient visits FY2021: 887,335 visits Outpatient visits FY2022: 944,523 visits Outpatient visits FY2023: 1,128,719 visits Outpatient visits FY2024: 1,137,742 visits Outpatient visits FY2025: 1,061,851 visits Inpatient visits FY2021: 45,977 visits Inpatient visits FY2022: 44,581 visits Inpatient visits FY2023: 67,258 visits Inpatient visits FY2024: 72,120 visits Inpatient visits FY2025: 69,747 visits
Period: complete fiscal years; metric definitions follow company disclosure; unit：visits；type: company disclosure. FY2021 formal disclosure, PDF page 10; FY2022 formal disclosure, PDF page 11; FY2023 formal disclosure, PDF page 10; FY2025 formal disclosure, PDF page 11
View exact values and source pages
MetricPeriodValueSource
Ophthalmic hospitals2025-12-3131 hospitalsPDF page 11
Optical centres2025-12-3132 centresPDF page 11
Outpatient visitsFY2021887,335 visitsPDF page 10
Inpatient visitsFY202145,977 visitsPDF page 10
Outpatient visitsFY2022944,523 visitsPDF page 11
Inpatient visitsFY202244,581 visitsPDF page 11
Outpatient visitsFY20231,128,719 visitsPDF page 10
Inpatient visitsFY202367,258 visitsPDF page 10
Outpatient visitsFY20241,137,742 visitsPDF page 11
Outpatient visitsFY20251,061,851 visitsPDF page 11
Inpatient visitsFY202472,120 visitsPDF page 11
Inpatient visitsFY202569,747 visitsPDF page 11

Structured disclosure

Cash flow

Net cash flows from operating activities

RMB 339.411 million FY2025 PDF page 27

Cash and cash equivalents

RMB 516.339 million 2025-12-31 PDF page 98

Annual series

Net cash flows from operating activities (RMB)

Net cash flows from operating activities (RMB), unit: RMB million 402 302 201 101 0 FY2021FY2022FY2023FY2024FY2025 Net cash flows from operating activities FY2021: 249.4 RMB million Net cash flows from operating activities FY2022: 273.4 RMB million Net cash flows from operating activities FY2023: 372.6 RMB million Net cash flows from operating activities FY2024: 354.4 RMB million Net cash flows from operating activities FY2025: 339.4 RMB million
Period: complete fiscal years; fiscal year-end follows company disclosure; unit：RMB million；type: company disclosure. FY2021 formal disclosure, PDF page 24; FY2022 formal disclosure, PDF page 26; FY2023 formal disclosure, PDF page 24; FY2024 formal disclosure, PDF page 27; FY2025 formal disclosure, PDF page 27
View exact values and source pages
MetricPeriodValueSource
Net cash flows from operating activitiesFY2021RMB 249.394 millionPDF page 24
Net cash flows from operating activitiesFY2022RMB 273.41 millionPDF page 26
Net cash flows from operating activitiesFY2023RMB 372.569 millionPDF page 24
Net cash flows from operating activitiesFY2024RMB 354.355 millionPDF page 27
Net cash flows from operating activitiesFY2025RMB 339.411 millionPDF page 27
Cash and cash equivalents2025-12-31RMB 516.339 millionPDF page 98

Structured disclosure

Shareholder returns

Annual series

Final dividend

Final dividend, unit: HKD per share 1 1 1 0 0 FY2021FY2022FY2023FY2024FY2025 Final dividend FY2021: 0.104 HKD per share Final dividend FY2022: 0.174 HKD per share Final dividend FY2023: 0.221 HKD per share Final dividend FY2024: 0.119 HKD per share Final dividend FY2025: 0.242 HKD per share
Period: complete fiscal years; dividend status follows each year's formal disclosure; unit：HKD per share；type: company disclosure. FY2021 formal disclosure, PDF page 7; FY2022 formal disclosure, PDF page 30; FY2023 formal disclosure, PDF page 27; FY2024 formal disclosure, PDF page 31; FY2025 formal disclosure, PDF page 31
View exact values and source pages
MetricPeriodValueSource
Final dividendFY2021HKD 0.104/shareProposed final dividend disclosed in the FY2021 annual report, subject to shareholder approval.PDF page 7
Final dividendFY2022HKD 0.174/shareProposed final dividend disclosed in the FY2022 annual report, subject to shareholder approval.PDF page 30
Final dividendFY2023HKD 0.221/shareProposed final dividend disclosed in the FY2023 annual report; a separate proposed special dividend of HKD0.0767 per share is excluded from this series.PDF page 27
Final dividendFY2024HKD 0.119/shareProposed final dividend disclosed in the FY2024 annual report, subject to shareholder approval.PDF page 31
Final dividendFY2025HKD 0.242/shareBoard recommendation disclosed in the FY2025 annual report, subject to shareholder approval.PDF page 31

Leadership profile

Senior management

Roles and biographies follow formal disclosure. Portraits are used only when published on the company’s official website.

1 / 4

Official market reference

Latest quote on HKEX

PureIR does not display or redistribute market-price data.

View 02219 on HKEX ↗

Formal disclosure

Principal risks

Pricing reform, procurement and competition

Medical-insurance pricing reform, volume-based procurement of intraocular lenses and industry competition may affect service pricing, revenue and margins; the company disclosed an impact on 2025 revenue.

HKEX · PDF page 11

Medical quality and licensing

Operation of hospitals and optical centres depends on medical-quality management, professionals and relevant licences; medical-safety or compliance events may affect the business and reputation.

HKEX · PDF page 7

Expansion and capital expenditure

Hospital upgrades, new facilities and acquisitions require continuing capital; year-end 2025 capital commitments were approximately RMB103.7 million, making cash flow and financing capacity relevant to expansion.

HKEX · PDF page 28

Structured deposits and wealth-management products

The Group allocates temporary surplus cash to bank wealth-management products and structured deposits; principal outstanding at year-end 2025 was RMB190.0 million, or 6.3% of total assets.

HKEX · PDF page 28

Evidence

Formal sources and public data

2025 Annual Report193 PDF pages2024 Annual Report201 PDF pages2023 Annual Report193 PDF pages2022 Annual Report185 PDF pages2021 Annual Report175 PDF pagesDownload structured JSON →